Yescarta (axicabtagene ciloleucel) is an advanced CAR T-cell therapy used to treat certain types of blood cancer, especially large B-cell lymphoma and follicular lymphoma in adults. It is different from regular chemotherapy because it is made using the patient’s own immune cells.

Yescarta is a one-time intravenous (IV) infusion given at a specialized cancer treatment center. Before the infusion, the patient’s T cells are collected and genetically modified so they can recognize and attack cancer cells carrying the CD19 protein.

Important: Yescarta can cause serious or life-threatening side effects, including cytokine release syndrome and neurological problems. It must be given under the supervision of a specialist team experienced in CAR T-cell therapy.

Yescarta: Quick Overview

The U.S. prescribing information specifies a target dose of 2 × 10⁶ CAR-positive viable T cells per kg, with a maximum of 2 × 10⁸ CAR-positive viable T cells.

What Is Yescarta?

Yescarta is a type of CAR T-cell immunotherapy. Its active ingredient is axicabtagene ciloleucel.

Unlike a conventional tablet or chemotherapy medicine, Yescarta is made from the patient’s own T cells. These immune cells are collected from the blood, modified in a specialized laboratory, and then returned to the patient through an IV infusion.

The modified cells are designed to recognize CD19, a protein found on many B-cell cancers. Once the CAR T cells recognize the cancer cells, they become activated and help destroy them.

Yescarta Uses

Yescarta is used for certain B-cell non-Hodgkin lymphomas in adults.

Current U.S. labeling includes:

1. Large B-Cell Lymphoma

Yescarta may be used in adults with large B-cell lymphoma when the cancer:

• Does not respond to first-line chemoimmunotherapy, or
• Comes back within 12 months after first-line chemoimmunotherapy, or
• Has returned or not responded after two or more lines of systemic treatment.

The approved large B-cell lymphoma indications include diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

2. Follicular Lymphoma

Yescarta is also approved for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy under the current U.S. label.

Important Note About Approved Uses

The approved uses of Yescarta can differ between countries and may change as regulators review new evidence. Patients should follow the indication approved by their country’s drug regulator and their oncologist’s recommendation.

How Does Yescarta Work?

Yescarta works differently from traditional chemotherapy.

The treatment process generally involves several steps.

Step 1: T-Cell Collection

Blood is collected from the patient using a process called leukapheresis. T cells are separated from the blood.

Step 2: T-Cell Modification

The collected T cells are genetically modified in a specialized laboratory. They are given a new receptor called a chimeric antigen receptor (CAR).

Step 3: CAR T-Cell Production

The modified cells are multiplied to produce enough CAR T cells for treatment.

Step 4: Preparation Before Infusion

Before Yescarta is given, the patient receives lymphodepleting chemotherapy. This prepares the body for the CAR T cells.

Step 5: Yescarta Infusion

The modified T cells are returned to the patient’s body through an IV infusion.

Step 6: Cancer Cell Attack

The CAR T cells recognize CD19 on certain cancer cells and become activated to attack those cells.

Yescarta Dosage

Yescarta does not have a conventional daily or weekly dose like a tablet.

The U.S. prescribing information gives a target dose of:

2 × 10⁶ CAR-positive viable T cells per kg body weight

The maximum dose is:

2 × 10⁸ CAR-positive viable T cells.

Yescarta is administered as a single IV infusion after the required preparation and lymphodepleting chemotherapy.

The exact treatment plan is determined by the CAR T-cell treatment team.

How Is Yescarta Given?

Yescarta is:

• Given intravenously
• Administered by trained healthcare professionals
• Given as a one-time infusion
• Used only in an appropriate specialized treatment setting

It is not a medicine that patients can take at home.

What Happens Before Yescarta Treatment?

Patients generally undergo several evaluations before CAR T-cell therapy.

Your treatment team may assess:

• Type and stage of cancer
• Previous cancer treatments
• Overall health
• Blood counts
• Heart and lung function
• Kidney and liver function
• Current or recent infections
• Neurological health

The patient’s T cells must also be collected and processed before the final Yescarta infusion.

Yescarta Side Effects

Yescarta can cause serious side effects. Some can be life-threatening, so patients need close medical monitoring after treatment.

The most important serious reactions include cytokine release syndrome (CRS) and neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS).

Common Yescarta Side Effects

Reported side effects can include:

• Fever
• Chills
• Low blood pressure
• Fatigue
• Fast heartbeat
• Headache
• Nausea
• Diarrhea
• Confusion
• Difficulty speaking
• Low red blood cell count
• Low white blood cell count
• Low platelet count
• Decreased appetite
• Tremor
• Low oxygen levels

The exact frequency depends on the disease being treated and the clinical study population.

Cytokine Release Syndrome (CRS)

Cytokine release syndrome is one of the most important risks of Yescarta.

CRS happens when the immune system becomes strongly activated after CAR T-cell treatment. It can cause inflammation throughout the body.

Possible symptoms include:

• Fever
• Chills
• Low blood pressure
• Fast heartbeat
• Difficulty breathing
• Low oxygen levels
• Dizziness
• Severe weakness

CRS can be life-threatening. The prescribing information recommends close monitoring and treatment with medicines such as tocilizumab, with corticosteroids used when appropriate for severe or life-threatening cases.

In clinical data for patients with non-Hodgkin lymphoma, CRS occurred frequently, although severe CRS was much less common.

Neurological Side Effects of Yescarta

Yescarta can also cause serious neurological side effects.

These may include:

• Confusion
• Difficulty speaking
• Tremors
• Sleepiness
• Headache
• Difficulty paying attention
• Memory problems
• Seizures
• Loss of coordination
• Changes in consciousness

These problems can occur during CRS or after CRS has improved. Patients need close monitoring after the infusion.

Other Important Yescarta Risks

Yescarta treatment can also cause:

Low Blood Cell Counts

Patients may develop low levels of:

• White blood cells
• Red blood cells
• Platelets

This can increase the risk of infections, anemia, and bleeding.

Infections

Because CAR T-cell therapy can affect the immune system, infections can occur.

Low Immunoglobulin Levels

Yescarta can reduce normal B cells and may lead to lower immunoglobulin levels, potentially increasing infection risk.

Secondary Cancers

The current U.S. prescribing information includes a warning about secondary T-cell malignancies following treatment with certain genetically modified autologous T-cell immunotherapies, including Yescarta. Long-term monitoring is recommended.

When Should You Get Emergency Medical Help?

After Yescarta treatment, contact your healthcare team or seek emergency medical attention immediately if you develop:

• Fever of 38°C (100.4°F) or higher
• Trouble breathing
• Severe dizziness
• Confusion
• Difficulty speaking
• Seizures
• Severe weakness
• Fast or irregular heartbeat
• Severe chills
• Severe nausea, vomiting, or diarrhea
• Loss of consciousness

These symptoms can be signs of serious complications such as CRS or neurological toxicity.

How Long Does Yescarta Treatment Take?

Yescarta itself is given as a one-time infusion, but the complete treatment process takes considerably longer.

It can include:

1. Medical evaluation
2. T-cell collection
3. Manufacturing of the CAR T cells
4. Lymphodepleting chemotherapy
5. Yescarta infusion
6. Close monitoring after infusion

Patients are generally required to remain close to a qualified healthcare facility after treatment because serious side effects can develop during the early post-infusion period. Current prescribing information advises monitoring at least daily for 7 days after infusion and remaining near a healthcare facility for at least 2 weeks.

What Should You Avoid After Yescarta?

Patients should follow their treatment team’s instructions carefully.

The current prescribing information advises patients to:

• Avoid driving for at least 2 weeks after infusion
• Stay near an appropriate healthcare facility for at least 2 weeks
• Report symptoms immediately
• Attend scheduled blood tests and follow-up appointments
• Tell other healthcare professionals that they have received Yescarta

Yescarta Price

Yescarta is not an ordinary retail medicine with a simple pharmacy price.

It is a personalized CAR T-cell therapy that requires cell collection, manufacturing, specialized treatment facilities, hospital care, and monitoring.

For this reason, the total treatment cost can be very high and varies significantly between countries and hospitals.

For reference, a NICE appraisal lists a UK list price of £280,451 for a single infusion, before the confidential NHS discount.

Older Indian reports have described imported CAR T-cell therapies such as Yescarta as costing several crores when treatment and hospital expenses are included. These figures should not be treated as a current Yescarta India price because costs, availability, taxes, hospital charges, and access arrangements can change.

Yescarta Price in India

There is no reliable single nationwide retail price that can be used for every Indian patient.

The actual cost may depend on:

• Treatment center
• Cell collection and manufacturing arrangements
• Hospitalization
• Doctor and specialist charges
• Laboratory tests
• Supportive medicines
• Management of complications
• Insurance or financial assistance
• Availability of the therapy

Patients should ask the treating cancer center for a current, itemized treatment estimate.

Is Yescarta a Chemotherapy?

No.

Yescarta is a CAR T-cell immunotherapy, not conventional chemotherapy.

However, patients generally receive chemotherapy called lymphodepleting chemotherapy before the CAR T-cell infusion. This prepares the immune system for the incoming CAR T cells.

Is Yescarta a Gene Therapy?

Yescarta is considered a genetically modified cellular therapy and is commonly described as a type of gene therapy.

The patient’s own T cells are genetically modified outside the body to express a CAR that recognizes CD19.

Is Yescarta a One-Time Treatment?

Yes. Yescarta is administered as a one-time CAR T-cell infusion.

However, one infusion does not mean the overall treatment experience is completed in one day. Patients need preparation before infusion and close monitoring afterward.

Yescarta and Pregnancy

There is limited information about the use of Yescarta during pregnancy.

Because Yescarta is a highly specialized cancer treatment, patients who are pregnant, planning pregnancy, or could become pregnant should discuss this with their oncology team before treatment.

Pregnancy and fertility considerations should be addressed before lymphodepleting chemotherapy and CAR T-cell treatment.

Yescarta and Breastfeeding

Patients should discuss breastfeeding with their cancer specialist.

Because Yescarta is a genetically modified cellular therapy and patients also receive chemotherapy and other medicines during treatment, the treating team should provide individualized advice about whether and when breastfeeding is appropriate.

Yescarta Drug Interactions

Yescarta itself is not taken like a conventional daily medicine, but patients may receive several medicines before, during, and after the infusion.

Tell your healthcare team about:

• Prescription medicines
• Over-the-counter medicines
• Vitamins
• Herbal supplements
• Cancer medicines
• Steroids
• Antibiotics
• Medicines for seizures

Your treatment team will decide which medicines should be continued, stopped, or adjusted.

Yescarta Contraindications and Precautions

Yescarta requires careful medical assessment.

Tell your doctor if you have:

• An active infection
• Recent infection
• Lung problems
• Heart disease
• Liver disease
• Kidney problems
• Previous neurological problems
• Seizures
• Stroke
• Memory problems
• Previous cancer treatments

The current prescribing information specifically warns against administering Yescarta to patients with active infection or inflammatory disorders.

Yescarta Benefits

For appropriately selected patients, Yescarta offers an important treatment option for certain aggressive or relapsed blood cancers.

Potential benefits include:

• Personalized treatment using the patient’s own immune cells
• Targeted recognition of CD19-positive cancer cells
• One-time CAR T-cell infusion
• An option for certain cancers that have returned or failed to respond to previous treatments

Clinical studies have shown meaningful responses in appropriately selected patients with certain forms of large B-cell lymphoma and follicular lymphoma.

However, Yescarta does not guarantee a cure. Response varies from patient to patient.

Frequently Asked Questions About Yescarta

What is Yescarta used for?

Yescarta is used to treat certain types of large B-cell lymphoma and follicular lymphoma in adults, particularly when the disease has not responded to or has returned after previous treatments.

What is the generic name of Yescarta?

The generic name is axicabtagene ciloleucel.

How is Yescarta given?

Yescarta is given as a one-time intravenous infusion by trained healthcare professionals at an appropriate treatment center.

What is the Yescarta dosage?

The U.S. prescribing information specifies a target dose of 2 × 10⁶ CAR-positive viable T cells/kg, with a maximum dose of 2 × 10⁸ CAR-positive viable T cells.

What are the most serious Yescarta side effects?

The major serious risks include cytokine release syndrome (CRS) and neurological toxicities, including ICANS.

Is Yescarta chemotherapy?

No. Yescarta is a CAR T-cell immunotherapy. Chemotherapy is generally used beforehand to prepare the body for CAR T-cell treatment.

How much does Yescarta cost?

Yescarta is a highly specialized therapy, so there is no single universal price. The total cost varies by country, treatment center, hospital services, manufacturing arrangements, and supportive care.

Can Yescarta cure lymphoma?

Yescarta can produce deep and long-lasting responses in some patients, but it does not guarantee that lymphoma will be cured. Your oncologist can explain the expected benefits based on your specific cancer and previous treatments.

How long should I stay near the hospital after Yescarta?

Current prescribing information advises patients to remain near a healthcare facility for at least 2 weeks after infusion because serious complications can occur during this period.

Final Words

Yescarta (axicabtagene ciloleucel) is a personalized CAR T-cell therapy used to treat certain types of B-cell non-Hodgkin lymphoma in adults. It uses the patient’s own T cells, which are genetically modified to recognize and attack CD19-positive cancer cells.

Unlike regular tablets or chemotherapy cycles, Yescarta is given as a one-time IV infusion. However, the complete treatment involves cell collection, laboratory manufacturing, preparative chemotherapy, infusion, and close follow-up.

The most important risks include cytokine release syndrome and neurological toxicity, which can be severe or life-threatening. Patients therefore need treatment at an experienced center with appropriate monitoring and emergency support.

The cost of Yescarta is very high and varies considerably. There is no dependable single retail price for India; patients should obtain a current estimate directly from the treating CAR T-cell center.

Medical Disclaimer

This article is for educational purposes only and should not replace advice from an oncologist or other qualified healthcare professional. Yescarta is a highly specialized cancer treatment with potentially life-threatening complications. It should only be used when recommended and administered by an appropriately trained medical team. Treatment decisions, dosage, eligibility, and expected outcomes must be determined by the patient’s cancer specialist.